Integra LifeSciences cuts FY2026 revenue and EPS outlook after Cincinnati flood
Integra LifeSciences announced preliminary Q3 2026 results and revised its full‑year guidance because flooding at its Cincinnati manufacturing plant disrupted production. The company now expects Q3 revenue of $410 million‑$412 million and adjusted EPS of $0.55‑$0.59, and it lowered FY2026 revenue to $1.634 billion‑$1.654 billion and adjusted EPS to $2.30‑$2.40. CEO Stuart Essig said insurance should offset much of the earnings impact and full‑site operations are targeted for Q2 2027.
Why it matters
The guidance cut reduces revenue expectations by up to $41 million and EPS by $0.10, which may pressure the stock price as investors adjust valuations (the company’s own release notes the impact). The company still expects $190 million‑$200 million of operating cash flow for the year, indicating cash generation remains strong.
Key facts
- 1Preliminary Q3 2026 revenue is projected at $410 million‑$412 million. globenewswire.com
- 2Preliminary Q3 2026 adjusted EPS is projected at $0.55‑$0.59. globenewswire.com
- 3Full‑year 2026 revenue guidance is revised to $1.634 billion‑$1.654 billion. globenewswire.com
- 4Full‑year 2026 adjusted EPS guidance is revised to $2.30‑$2.40. globenewswire.com
- 5The July flood is estimated to cut Q3 revenue by about $7 million and Q4 revenue by $15 million‑$20 million. globenewswire.com
- 6Operating cash flow is expected to exceed $85 million in Q3 and $190 million‑$200 million for the full year. globenewswire.com
Summary written by AlphAI from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.